

BEFORE THE  
MEDICAL BOARD OF CALIFORNIA  
DEPARTMENT OF CONSUMER AFFAIRS  
STATE OF CALIFORNIA

In the Matter of the First Amended  
Accusation Against:

Ali Mokhlesi, M.D.

Physician's & Surgeon's  
Certificate No. C 51972

Respondent.

Case No. 800-2019-055815

DECISION

The attached Stipulated Settlement and Disciplinary Order is hereby adopted as the Decision and Order of the Medical Board of California, Department of Consumer Affairs, State of California.

This Decision shall become effective at 5:00 p.m. on May 29, 2023.

IT IS SO ORDERED: April 28, 2023.

MEDICAL BOARD OF CALIFORNIA



---

Richard E. Thorp, M.D., Chair  
Panel B

1 ROB BONTA  
Attorney General of California  
2 STEVE DIEHL  
Supervising Deputy Attorney General  
3 JOHN S. GATSCHET  
Deputy Attorney General  
4 State Bar No. 244388  
California Department of Justice  
5 1300 I Street, Suite 125  
P.O. Box 944255  
6 Sacramento, CA 94244-2550  
Telephone: (916) 210-7546  
7 Facsimile: (916) 327-2247

8 *Attorneys for Complainant*

9  
10 **BEFORE THE**  
11 **MEDICAL BOARD OF CALIFORNIA**  
12 **DEPARTMENT OF CONSUMER AFFAIRS**  
13 **STATE OF CALIFORNIA**

14 In the Matter of the First Amended Accusation  
Against:  
15 **ALI MOKHLESI, M.D.**  
11795 Education Street # 100  
16 Auburn, CA 95602  
17 Physician's and Surgeon's Certificate  
No. C 51972  
18 Respondent.  
19

Case No. 800-2019-055815

OAH No. 2021020285

**STIPULATED SETTLEMENT AND  
DISCIPLINARY ORDER**

20  
21 **IT IS HEREBY STIPULATED AND AGREED** by and between the parties to the above-  
22 entitled proceedings that the following matters are true:

23 **PARTIES**

24 1. Reji Varghese ("Complainant") is the Deputy Director of the Medical Board of  
25 California ("Board"). He brought this action solely in his official capacity and is represented in  
26 this matter by Rob Bonta, Attorney General of the State of California, by John S. Gatschet,  
27 Deputy Attorney General.

28 ///



1 8. Respondent voluntarily, knowingly, and intelligently waives and gives up each and  
2 every right set forth above.

3 **CULPABILITY**

4 9. Respondent understands and agrees that the charges and allegations in First Amended  
5 Accusation No. 800-2019-055815, if proven at a hearing, constitute cause for imposing discipline  
6 upon his Physician's and Surgeon's Certificate.

7 10. Respondent agrees that, at a hearing, Complainant could establish a *prima facie* basis  
8 for the charges in the First Amended Accusation, and that Respondent hereby gives up his right to  
9 contest those charges.

10 11. Respondent agrees that his Physician's and Surgeon's Certificate is subject to  
11 discipline and he agrees to be bound by the Board's probationary terms as set forth in the  
12 Disciplinary Order below.

13 **CONTINGENCY**

14 12. This stipulation shall be subject to approval by the Medical Board of California.  
15 Respondent understands and agrees that counsel for Complainant and the staff of the Medical  
16 Board of California may communicate directly with the Board regarding this stipulation and  
17 settlement, without notice to or participation by Respondent or his counsel. By signing the  
18 stipulation, Respondent understands and agrees that he may not withdraw his agreement or seek  
19 to rescind the stipulation prior to the time the Board considers and acts upon it. If the Board fails  
20 to adopt this stipulation as its Decision and Order, the Stipulated Settlement and Disciplinary  
21 Order shall be of no force or effect, except for this paragraph, it shall be inadmissible in any legal  
22 action between the parties, and the Board shall not be disqualified from further action by having  
23 considered this matter.

24 13. The parties understand and agree that Portable Document Format (PDF) and facsimile  
25 copies of this Stipulated Settlement and Disciplinary Order, including PDF and facsimile  
26 signatures thereto, shall have the same force and effect as the originals.

27 ///

28 ///

1 14. In consideration of the foregoing admissions and stipulations, the parties agree that  
2 the Board may, without further notice or opportunity to be heard by the Respondent, issue and  
3 enter the following Disciplinary Order:

4 **DISCIPLINARY ORDER**

5 **A. PUBLIC REPRIMAND**

6 **IT IS HEREBY ORDERED THAT** the Physician's and Surgeon's Certificate No. C  
7 51972 issued to Respondent Ali Mokhlesi, M.D. shall be and is hereby publically reprimanded  
8 pursuant to California Business and Professions Code section 2227, subdivision (a)(4). This  
9 Public Reprimand, which is issued in connection with First Amended Accusation No. 800-2019-  
10 055815, is as follows:

11 "On or between November 19, 2013, and May 2019, while treating Patients 1, 2, 3, and 4,  
12 you failed to meet the standard of care for the proper prescription of controlled substances as  
13 more fully described in First Amended Accusation No. 800-2019-055815."

14 **B. PRESCRIBING PRACTICES COURSE**

15 Within 60 calendar days of the effective date of this Decision, Respondent shall enroll in a  
16 course in prescribing practices approved in advance by the Board or its designee. Respondent  
17 shall provide the approved course provider with any information and documents that the approved  
18 course provider may deem pertinent. Respondent shall participate in and successfully complete  
19 the classroom component of the course not later than six (6) months after Respondent's initial  
20 enrollment. Respondent shall successfully complete any other component of the course within  
21 one (1) year of enrollment. The prescribing practices course shall be at Respondent's expense  
22 and shall be in addition to the Continuing Medical Education (CME) requirements for renewal of  
23 licensure.

24 A prescribing practices course taken after the acts that gave rise to the charges in the  
25 Accusation, but prior to the effective date of the Decision may, in the sole discretion of the Board  
26 or its designee, be accepted towards the fulfillment of this condition if the course would have  
27 been approved by the Board or its designee had the course been taken after the effective date of  
28 this Decision. On or about April 26-28, 2021, Respondent attended and completed the U.C. San

1 Diego PACE programs' "Physician Prescribing Course."

2 Respondent shall submit a certification of successful completion to the Board or its  
3 designee not later than 15 calendar days after successfully completing the course, or not later than  
4 15 calendar days after the effective date of the Decision, whichever is later. Respondent may  
5 submit the certificate of completion from the April 26-28, 2021, "Physician Prescribing Course"  
6 to satisfy this term.

7 **C. MEDICAL RECORD KEEPING COURSE**

8 Within 60 calendar days of the effective date of this Decision, Respondent shall enroll in a  
9 course in medical record keeping approved in advance by the Board or its designee. Respondent  
10 shall provide the approved course provider with any information and documents that the approved  
11 course provider may deem pertinent. Respondent shall participate in and successfully complete  
12 the classroom component of the course not later than six (6) months after Respondent's initial  
13 enrollment. Respondent shall successfully complete any other component of the course within  
14 one (1) year of enrollment. The medical record keeping course shall be at Respondent's expense  
15 and shall be in addition to the Continuing Medical Education (CME) requirements for renewal of  
16 licensure.

17 A medical record keeping course taken after the acts that gave rise to the charges in the  
18 Accusation, but prior to the effective date of the Decision may, in the sole discretion of the Board  
19 or its designee, be accepted towards the fulfillment of this condition if the course would have  
20 been approved by the Board or its designee had the course been taken after the effective date of  
21 this Decision. On or about April 29-30, 2021, Respondent attended and completed the U.C. San  
22 Diego PACE programs' Medical Record Keeping Course.

23 Respondent shall submit a certification of successful completion to the Board or its  
24 designee not later than 15 calendar days after successfully completing the course, or not later than  
25 15 calendar days after the effective date of the Decision, whichever is later. Respondent may  
26 submit the certificate of completion from the April 29-30, 2021, "Medical Record Keeping  
27 Course" to satisfy this term.

28 ///

1                   **D. PROFESSIONALISM PROGRAM (ETHICS COURSE)**

2                   Within 60 calendar days of the effective date of this Decision, Respondent shall enroll in a  
3 professionalism program, that meets the requirements of Title 16, California Code of Regulations  
4 (CCR) section 1358.1. Respondent shall participate in and successfully complete that program.  
5 Respondent shall provide any information and documents that the program may deem pertinent.  
6 Respondent shall successfully complete the classroom component of the program not later than  
7 six (6) months after Respondent's initial enrollment, and the longitudinal component of the  
8 program not later than the time specified by the program, but no later than one (1) year after  
9 attending the classroom component. The professionalism program shall be at Respondent's  
10 expense and shall be in addition to the Continuing Medical Education (CME) requirements for  
11 renewal of licensure.

12                   A professionalism program taken after the acts that gave rise to the charges in the  
13 Accusation, but prior to the effective date of the Decision may, in the sole discretion of the Board  
14 or its designee, be accepted towards the fulfillment of this condition if the program would have  
15 been approved by the Board or its designee had the program been taken after the effective date of  
16 this Decision. On or about January 7, 2023, Respondent enrolled to take the Western Institute of  
17 Legal Medicine, Inc.'s "Medical Ethics and Professionalism Course" scheduled to take place  
18 January 22-23, 2023.

19                   Respondent shall submit a certification of successful completion to the Board or its  
20 designee not later than 15 calendar days after successfully completing the program or not later  
21 than 15 calendar days after the effective date of the Decision, whichever is later. Upon successful  
22 completion of the January 22-23, 2023, "Medical Ethics and Professionalism Course,"  
23 Respondent may submit the certificate from that course to satisfy this condition.

24                   **E. CLINICAL COMPETENCE ASSESSMENT PROGRAM**

25                   Within 60 calendar days of the effective date of this Decision, Respondent shall enroll in a  
26 clinical competence assessment program approved in advance by the Board or its designee.  
27 Respondent shall successfully complete the program not later than one (1) year after  
28 Respondent's initial enrollment unless the Board or its designee agrees in writing to an extension

1 of that time.

2 The program shall consist of a comprehensive assessment of Respondent's physical and  
3 mental health and the six general domains of clinical competence as defined by the Accreditation  
4 Council on Graduate Medical Education and American Board of Medical Specialties pertaining to  
5 Respondent's current or intended area of practice. The program shall take into account data  
6 obtained from the pre-assessment, self-report forms and interview, and the Decision(s),  
7 Accusation(s), and any other information that the Board or its designee deems relevant. The  
8 program shall require Respondent's on-site participation for a minimum of three (3) and no more  
9 than five (5) days as determined by the program for the assessment and clinical education  
10 evaluation. Respondent shall pay all expenses associated with the clinical competence  
11 assessment program.

12 At the end of the evaluation, the program will submit a report to the Board or its designee  
13 which unequivocally states whether the Respondent has demonstrated the ability to practice  
14 safely and independently. Based on Respondent's performance on the clinical competence  
15 assessment, the program will advise the Board or its designee of its recommendation(s) for the  
16 scope and length of any additional educational or clinical training, evaluation or treatment for any  
17 medical condition or psychological condition, or anything else affecting Respondent's practice of  
18 medicine. Respondent shall comply with the program's recommendations.

19 Determination as to whether Respondent successfully completed the clinical competence  
20 assessment program is solely within the program's jurisdiction.

21 **F. INVESTIGATION/ENFORCEMENT COST RECOVERY**

22 Respondent is hereby ordered to reimburse the Board its costs of investigation and  
23 enforcement, including, but not limited to, expert review, amended accusations, legal reviews,  
24 investigation, as applicable, in the amount of **\$15,000.00** (fifteen thousand dollars). Costs shall  
25 be due and payable to the Medical Board of California.

26 Payment must be made in full within ninety (90) days of the effective date of the Order.  
27 The filing of bankruptcy by Respondent shall not relieve Respondent of the responsibility to  
28 repay investigation and enforcement costs, including expert review costs. This condition shall be



1 monitored by the Probation Department.

2 **G. FAILURE TO COMPLY**


3 If Respondent fails to enroll, participate in, or successfully complete the educational  
4 program or course, described in conditions B, C, D, and E, within the designated time period set  
5 forth in each condition, Respondent shall receive and comply with a notification from the Board  
6 or its designee to cease the practice of medicine within three (3) calendar days after being so  
7 notified. Respondent shall not resume the practice of medicine until enrollment or participation  
8 in the educational program(s) or course(s) has been completed as required by the express  
9 language of the Decision and Order. In addition, failure to successfully complete the education  
10 program(s) or course(s) outlined above shall also constitute general unprofessional conduct and is  
11 grounds for further immediate disciplinary action.

12 If Respondent fails to reimburse the Board as described in condition F, within the  
13 designated time period, Respondent shall receive and comply with a notification from the Board  
14 or its designee to cease the practice of medicine within three (3) calendar days after being so  
15 notified. Respondent shall not resume the practice of medicine until the full payment of the  
16 investigative and enforcement costs have been paid to the Board. In addition, failure to  
17 successfully reimburse the Board as outlined above shall also constitute general unprofessional  
18 conduct and is grounds for further immediate disciplinary action.


19 ///  
20 ///  
21 ///  
22 ///  
23 ///  
24 ///  
25 ///  
26 ///  
27 ///  
28 ///

ACCEPTANCE

I have carefully read the above Stipulated Settlement and Disciplinary Order and have fully discussed it with my attorney, Nicole D. Hendrickson. I understand the stipulation and the effect it will have on my Physician's and Surgeon's Certificate. I enter into this Stipulated Settlement and Disciplinary Order voluntarily, knowingly, and intelligently, and agree to be bound by the Decision and Order of the Medical Board of California.

DATED: 1/12/23   
ALI MOKHLESI, M.D.  
Respondent

I have read and fully discussed with Respondent Ali Mokhlesi, M.D. the terms and conditions and other matters contained in the above Stipulated Settlement and Disciplinary Order. I approve its form and content.


DATED: 01/13/2023   
NICOLE D. HENDRICKSON  
Attorney for Respondent

ENDORSEMENT

The foregoing Stipulated Settlement and Disciplinary Order is hereby respectfully submitted for consideration by the Medical Board of California.

DATED: January 13, 2023

Respectfully submitted,  
ROB BONTA  
Attorney General of California  
STEVE DIEHL  
Supervising Deputy Attorney General

  
JOHN S. GATSCHET  
Deputy Attorney General  
Attorneys for Complainant

SA2020303664  
36845590.docx

**Exhibit A**

**First Amended Accusation No. 800-2019-055815**

1 XAVIER BECERRA  
Attorney General of California  
2 STEVEN D. MUNI  
Supervising Deputy Attorney General  
3 JOHN S. GATSCHET  
Deputy Attorney General  
4 State Bar No. 244388  
California Department of Justice  
5 1300 I Street, Suite 125  
P.O. Box 944255  
6 Sacramento, CA 94244-2550  
Telephone: (916) 210-7546  
7 Facsimile: (916) 327-2247

8 *Attorneys for Complainant*

9

10

**BEFORE THE  
MEDICAL BOARD OF CALIFORNIA  
DEPARTMENT OF CONSUMER AFFAIRS  
STATE OF CALIFORNIA**

11

12

13

14

In the Matter of the First Amended Accusation  
Against:

Case No. 800-2019-055815

15

**Ali Mikhlesi, M.D.  
11795 Education Street, Suite #100  
Auburn, CA 95602**

**FIRST AMENDED  
A C C U S A T I O N**

16

17

Physician's and Surgeon's Certificate  
No. C 51972,

18

19

Respondent.

20

21

1. William Prasifka ("Complainant") brings this First Amended Accusation solely in his  
22 official capacity as the Executive Director of the Medical Board of California, Department of  
23 Consumer Affairs ("Board").

24

2. On or about June 8, 2005, the Board issued Physician's and Surgeon's Certificate  
25 Number C 51972 to Ali Mikhlesi, M.D. ("Respondent"). That certificate was in full force and  
26 effect at all times relevant to the charges brought herein and will expire on November 30, 2022,  
27 unless renewed.

28

///

1 JURISDICTION

2 3. On November 17, 2020, the Board properly filed an Accusation in Case No. 800-  
3 2019-055815 and served that Accusation on Respondent's address of record with the Board. The  
4 First Amended Accusation contains the same allegations and causes for discipline that were  
5 alleged in the Accusation filed on November 17, 2020.

6 4. This First Amended Accusation is brought before the Board, under the authority of  
7 the following laws. All section references are to the Business and Professions Code ("Code")  
8 unless otherwise indicated.

9 5. Section 2227 of the Code provides, in pertinent part, that a licensee who is found  
10 guilty under the Medical Practice Act may have his or her license revoked, suspended for a period  
11 not to exceed one year, placed on probation and required to pay the costs of probation monitoring,  
12 or such other action taken in relation to discipline as the Board deems proper.

13 6. Section 2228.1 of the Code, states in pertinent part:

14 (a) On and after July 1, 2019, except as otherwise provided in subdivision (c), the  
15 board shall require a licensee to provide a separate disclosure that includes the licensee's  
16 probation status, the length of the probation, the probation end date, all practice restrictions  
17 placed on the licensee by the board, the board's telephone number, and an explanation of  
18 how the patient can find further information on the licensee's probation on the licensee's  
19 profile page on the board's online license information Internet Web site, to a patient or the  
20 patient's guardian or health care surrogate before the patient's first visit following the  
21 probationary order while the licensee is on probation pursuant to a probationary order made  
22 on and after July 1, 2019, in any of the following circumstances:

23 (1) A final adjudication by the board following an administrative hearing or admitted  
24 findings or prima facie showing in a stipulated settlement establishing any of the following:

25 ...

26 (D) Inappropriate prescribing resulting in harm to patients and a probationary period  
27 of five years or more.

28 (2) An accusation or statement of issues alleged that the licensee committed any of  
the acts described in subparagraphs (A) to (D), inclusive, of paragraph (1), and a stipulated  
settlement based upon a nolo contendere or other similar compromise that does not include  
any prima facie showing or admission of guilt or fact but does include an express  
acknowledgment that the disclosure requirements of this section would serve to protect the  
public interest.

1 (b) A licensee required to provide a disclosure pursuant to subdivision (a) shall obtain  
2 from the patient, or the patient's guardian or health care surrogate, a separate, signed copy  
of that disclosure.

3 (c) A licensee shall not be required to provide a disclosure pursuant to subdivision (a)  
4 if any of the following applies:

5 (1) The patient is unconscious or otherwise unable to comprehend the disclosure and  
6 sign the copy of the disclosure pursuant to subdivision (b) and a guardian or health care  
surrogate is unavailable to comprehend the disclosure and sign the copy.

7 (2) The visit occurs in an emergency room or an urgent care facility or the visit is  
8 unscheduled, including consultations in inpatient facilities.

9 (3) The licensee who will be treating the patient during the visit is not known to the  
10 patient until immediately prior to the start of the visit.

11 (4) The licensee does not have a direct treatment relationship with the patient.

12 (d) On and after July 1, 2019, the board shall provide the following information, with  
13 respect to licensees on probation and licensees practicing under probationary licenses, in  
14 plain view on the licensee's profile page on the board's online license information Internet  
Web site.

15 (1) For probation imposed pursuant to a stipulated settlement, the causes alleged in  
16 the operative accusation along with a designation identifying those causes by which the  
licensee has expressly admitted guilt and a statement that acceptance of the settlement is not  
an admission of guilt.

17 (2) For probation imposed by an adjudicated decision of the board, the causes for  
18 probation stated in the final probationary order.

19 (3) For a licensee granted a probationary license, the causes by which the  
20 probationary license was imposed.

21 (4) The length of the probation and end date.

22 (5) All practice restrictions placed on the license by the board.

23 (e) Section 2314 shall not apply to this section.

24 7. Section 2234 of the Code, states in pertinent part:

25 The board shall take action against any licensee who is charged with  
26 unprofessional conduct. In addition to other provisions of this article, unprofessional  
conduct includes, but is not limited to, the following:

27 (a) Violating or attempting to violate, directly or indirectly, assisting in or  
28 abetting the violation of, or conspiring to violate any provision of this chapter.

1 (b) Gross negligence.

2 (c) Repeated negligent acts. To be repeated, there must be two or more  
3 negligent acts or omissions. An initial negligent act or omission followed by a  
4 separate and distinct departure from the applicable standard of care shall constitute  
5 repeated negligent acts.

6 (1) An initial negligent diagnosis followed by an act or omission medically  
7 appropriate for that negligent diagnosis of the patient shall constitute a single  
8 negligent act.

9 (2) When the standard of care requires a change in the diagnosis, act, or  
10 omission that constitutes the negligent act described in paragraph (1), including, but  
11 not limited to, a reevaluation of the diagnosis or a change in treatment, and the  
12 licensee's conduct departs from the applicable standard of care, each departure  
13 constitutes a separate and distinct breach of the standard of care.

14 ...

15 **COST RECOVERY**

16 8. Section 125.3<sup>1</sup> of the Code, states in pertinent part:

17 (a) Except as otherwise provided by law, in any order issued in resolution of a  
18 disciplinary proceeding before any board within the department or before the Osteopathic  
19 Medical Board, upon request of the entity bringing the proceeding, the administrative law  
20 judge may direct a licensee found to have committed a violation or violations of the  
21 licensing act to pay a sum not to exceed the reasonable costs of the investigation and  
22 enforcement of the case.

23 (b) In the case of a disciplined licensee that is a corporation or a partnership, the order  
24 may be made against the licensed corporate entity or licensed partnership.

25 (c) A certified copy of the actual costs, or a good faith estimate of costs where actual  
26 costs are not available, signed by the entity bringing the proceeding or its designated  
27 representative shall be prima facie evidence of reasonable costs of investigation and  
28 prosecution of the case. The costs shall include the amount of investigative and  
enforcement costs up to the date of the hearing, including, but not limited to, charges  
imposed by the Attorney General.

<sup>1</sup> Effective January 1, 2022. As amended by 2021 Cal.Legs.Serv.Ch. 649 (S.B. 806)(WEST), the Board will be seeking costs of investigation and enforcement incurred after January 1, 2022, to comply with the legislature's intent that investigative and enforcement costs be imposed in Medical Board disciplinary matters. The Board's amendment of the Accusation to add Bus. & Prof. Code section 125.3 does not involve the statute of limitations pursuant to Bus. & Prof. Code section 2230.5. The underlying allegations upon which the Board will make findings related to whether the Respondent committed unprofessional conduct were filed before the expiration of the statute of limitations. The collection of costs for the investigation and prosecution of the disciplinary matter is instead related to the imposition of discipline. The amendment to add Bus. & Prof. Code 125.3 is in line with the express legislative intent of the California legislature in Senate Bill 806.

1 (d) The administrative law judge shall make a proposed finding of the amount of  
2 reasonable costs of investigation and prosecution of the case when requested pursuant to  
3 subdivision (a). The finding of the administrative law judge with regard to costs shall not be  
4 reviewable by the board to increase the cost award. The board may reduce or eliminate the  
5 cost award, or remand to the administrative law judge if the proposed decision fails to make  
6 a finding on costs requested pursuant to subdivision (a).

7 (e) If an order for recovery of costs is made and timely payment is not made as  
8 directed in the board's decision, the board may enforce the order for repayment in any  
9 appropriate court. This right of enforcement shall be in addition to any other rights the  
10 board may have as to any licensee to pay costs.

11 (f) In any action for recovery of costs, proof of the board's decision shall be  
12 conclusive proof of the validity of the order of payment and the terms for payment.

13 (g)(1) Except as provided in paragraph (2), the board shall not renew or reinstate the  
14 license of any licensee who has failed to pay all of the costs ordered under this section.

15 (2) Notwithstanding paragraph (1), the board may, in its discretion, conditionally  
16 renew or reinstate for a maximum of one year the license of any licensee who demonstrates  
17 financial hardship and who enters into a formal agreement with the board to reimburse the  
18 board within that one-year period for the unpaid costs.

#### 19 DEFINITIONS

20 9. Fentanyl – Generic name for the drug Duragesic. Fentanyl is a potent, synthetic  
21 opioid analgesic with a rapid onset and short duration of action used for pain. The fentanyl  
22 transdermal patch is used for the treatment of long-term chronic pain. It has an extremely high  
23 danger of abuse and can lead to addiction as the medication is estimated to be 80 times more  
24 potent than morphine and hundreds of more times more potent than heroin.<sup>2</sup> Fentanyl is a  
25 Schedule II controlled substance pursuant to Code of Federal Regulations Title 21 section  
26 1308.12. Fentanyl is a dangerous drug pursuant to Business and Professions Code section 4022  
27 and is a Schedule II controlled substance pursuant to California Health and Safety Code section  
28 11055 subdivision (c).

10. Hydrocodone with acetaminophen – Generic name for the drugs Vicodin, Norco, and  
Lortab. Hydrocodone with acetaminophen is classified as an opioid analgesic combination  
product used to treat moderate to moderately severe pain. Hydrocodone with acetaminophen is a

<sup>2</sup> [http://www.cdc.gov/niosh/ershdb/EmergencyResponseCard\\_29750022.html](http://www.cdc.gov/niosh/ershdb/EmergencyResponseCard_29750022.html)



1 Schedule II controlled substance pursuant to Code of Federal Regulations Title 21 section  
2 1308.12.<sup>3</sup> Hydrocodone with acetaminophen is a dangerous drug pursuant to California Business  
3 and Professions Code section 4022 and is a Schedule II controlled substance pursuant to  
4 California Health and Safety Code section 11055, subdivision (b).

5 11. Oxycodone – Generic name for Roxicodone and Oxecta. Oxycodone has a high risk  
6 for addiction and dependence. It can cause respiratory distress and death when taken in high  
7 doses or when combined with other substances, especially alcohol. Oxycodone is a short-acting  
8 opioid analgesic used to treat moderate to severe pain. Oxycodone can also come in a long-acting  
9 formulation known as Oxycontin-ER. This formulation allows for extended release of the  
10 medication. Oxycodone is a Schedule II controlled substance pursuant to Code of Federal  
11 Regulations Title 21 section 1308.12. Oxycodone is a dangerous drug pursuant to California  
12 Business and Professions Code section 4022, and is a Schedule II controlled substance pursuant  
13 to California Health and Safety Code section 11055 subdivision (b).

14 12. Diazepam – Generic name for Valium. Diazepam is a long-acting member of the  
15 benzodiazepine family used for the treatment of anxiety and panic attacks. Diazepam is a  
16 Schedule IV controlled substance pursuant to Code of Federal Regulations Title 21 section  
17 1308.14 subdivision (c) and Health and Safety Code section 11057, subdivision (d), and a  
18 dangerous drug pursuant to Business and Professions Code section 4022.

19 13. Zolpidem tartrate – Generic name for Ambien. Zolpidem tartrate is a sedative and  
20 hypnotic used for short-term treatment of insomnia. Zolpidem tartrate is a Schedule IV controlled  
21 substance pursuant to Code of Federal Regulations Title 21 section 1308.14 subdivision (c). It is  
22 a Schedule IV controlled substance pursuant to Health and Safety Code section 11057,  
23 subdivision (d), and a dangerous drug pursuant to Business and Professions Code section 4022.

24 14. Morphine sulfate – Generic name for the drug MS Contin. Morphine is an opioid  
25 analgesic drug. It is the main psychoactive chemical in opium. Like other opioids, such as  
26 oxycodone, hydromorphone, and heroin, morphine acts directly on the central nervous system

27  
28 <sup>3</sup> Prior to October 6, 2014, hydrocodone with acetaminophen was a Schedule III  
controlled substance pursuant to Code of Federal Regulations Title 21 section 1308.13(e).

1 (CNS) to relieve pain. Morphine is a Schedule II controlled substance pursuant to Code of  
2 Federal Regulations Title 21 section 1308.12. Morphine is a Schedule II controlled substance  
3 pursuant to Health and Safety Code 11055, subdivision (b), and a dangerous drug pursuant to  
4 Business and Professions Code section 4022.

5 15. Methadone – Generic name for the drug Symoron. Methadone is a synthetic opioid.  
6 It is used medically as an analgesic and a maintenance anti-addictive and reductive preparation  
7 for use by patients with opioid dependence. Methadone is a Schedule II controlled substance  
8 pursuant to Code of Federal Regulations Title 21 section 1308.12. It is a Schedule II controlled  
9 substance pursuant to Health and Safety Code 11055, subdivision (c), and a dangerous drug  
10 pursuant to Business and Professions Code section 4022.

11 16. Temazepam – Generic name for the drug Restoril. Temazepam is used on a short-  
12 term basis to treat insomnia. Temazepam is a Schedule IV controlled substance pursuant to Code  
13 of Federal Regulations Title 21 section 1308.14 subdivision (c) and Health and Safety Code  
14 section 11057, subdivision (d), and a dangerous drug pursuant to Business and Professions Code  
15 section 4022.

### 16 FACTUAL ALLEGATIONS

#### 17 Patient 1

18 17. Patient 1<sup>4</sup> first began seeing the Respondent in 2006<sup>5</sup> after the Respondent joined the  
19 medical practice where she was an existing patient. Patient 1 suffered from severe chronic pain,  
20 which she described as being caused by constant back pain and joint pains. A CT scan conducted  
21 in 2003 indicated that Patient 1 had severe spinal stenosis. Patient 1 had prior diagnoses of  
22 myalgia, myositis, and fibromyalgia. Patient 1 also had a history of depression and was on  
23 antidepressant medication. According to the Respondent, Patient 1 was already receiving  
24 prescriptions of high dose opioids at the time that he took over her care. Patient 1 was relatively  
25 immobile and required 24 hour care by her children.

26 \_\_\_\_\_  
27 <sup>4</sup> All witnesses have been identified by numerical characters in order to protect  
confidentiality. All witnesses will be fully identified in discovery.

28 <sup>5</sup> Conduct occurring before November 19, 2013, is for historical context only and does not  
serve as an independent basis for discipline.

1           18. On or about December 2013, the Respondent prescribed a monthly prescription of  
2 180 tablets of 10-325 mg hydrocodone with acetaminophen and 60 tablets of 100 mg morphine  
3 sulfate to Patient 1. That prescription continued on a monthly basis until August 2018. In  
4 addition, Patient 1 received Lyrica, a Schedule V controlled substance, from October 2012 until  
5 February 2018 on a regular basis. As prescribed, the Respondent's prescriptions to Patient 1  
6 between December 2013 and August 2018 had a Morphine Equivalent Dose of 260 MED.<sup>6</sup> A  
7 review of a CURES<sup>7</sup> report on Patient 1 indicates that the Respondent began to taper down  
8 Patient 1's opioid prescriptions starting in August 2018. For example, in May 2019, the  
9 Respondent prescribed a monthly prescription of 60 tablets of 60 mg. morphine sulfate, 60 tablets  
10 of 15 mg. morphine sulfate, and 120 tablets of 10-325 mg. hydrocodone with acetaminophen to  
11 Patient 1. As prescribed, the Respondent's prescription to Patient 1 in May 2019 had a MED of  
12 190.

13           19. Between December 2013 and May 2019, the Respondent failed to provide a clear  
14 treatment plan and assessment for the conditions necessitating the continued prescribing of  
15 controlled substances. For example, the Respondent failed to document that Patient 1 had "severe  
16 spinal stenosis" in the medical chart despite it being previously evidenced in a 2003 scan.  
17 Respondent originally documented that he prescribed MS Contin for myalgia and myositis but  
18 over time began associating the prescription with a lumbar fracture, knee pain, history of a  
19 recurrent vertebral fracture and mid-line pain. The Respondent failed to document why he  
20 changed the treatment plan for MS Contin to treat those conditions. During an interview with the  
21 Board, the Respondent stated that Patient 1 appeared to suffer from Fibromyalgia but he failed to  
22 adequately document Fibromyalgia in his treatment notes and never fully addressed Fibromyalgia  
23 in Patient 1's medical record.

24  
25 <sup>6</sup> Morphine Equivalent Dose ("MED"), is a numerical standard against which most  
26 opioids can be compared, yielding an apples-to-apples comparison of each medication's potency.  
27 The California Medical Board Guidelines issued in November 2014 stated that any physicians  
28 should proceed cautiously (yellow flag warning) once an MED reaches 80 mg per day.  
[http://www.mbc.ca.gov/Licensees/Prescribing/Pain\\_Guidelines.pdf](http://www.mbc.ca.gov/Licensees/Prescribing/Pain_Guidelines.pdf) at page 17.

<sup>7</sup> Controlled Substance Utilization Review and Evaluation System (CURES) is a database  
maintained by the California Department of Justice, which tracks all controlled drug prescriptions  
that are dispensed in the State of California.

1           20. Between December 2013 and May 2019, the Respondent failed to examine the source  
2 of why Patient 1 suffered from a neurogenic bladder and whether her medications were causing  
3 urinary retention. The Respondent failed to discuss the fact that Patient 1's bedridden status may  
4 have contributed to her compression fracture due to osteopenia, nor did he discuss osteopenia in  
5 his treatment notes. The Respondent failed to use pain scales or urine toxicology screens as part  
6 of a treatment plan and periodic review of Patient 1's controlled substances despite prescribing  
7 high dose opioids to Patient 1. Between December 2013 and May 2019, the respondent failed to  
8 document that he could not provide urine toxicology screens through Patient 1's medical provider  
9 group. The Respondent failed to document on-going objective testing as part of a treatment plan  
10 and instead his periodic review of Patient 1's pain conditions relied heavily on Patient 1 and  
11 Patient 1's family's subjective report of pain.

12           21. On or about September 3, 2014, and February 13, 2017, Patient 1 entered into and  
13 signed a pain management agreement with the Respondent. The pain management agreement  
14 included information that stated pain medications can cause side effects including making the  
15 person sleepy and slow down reflexes, that alcohol can make pain medication side effects worse,  
16 and that pain medications with narcotics can be addictive. In July 2014, Patient 1's family  
17 members requested Ativan for Patient 1 because Patient 1 was suffering from withdrawal  
18 symptoms following a bowel cleanse. On or about July 25, 2014, the Respondent documented  
19 that Ativan was unnecessary as the absorption issues would resolve and that, "with all the  
20 medications (Patient 1) was taking, we do not want to sedate her brain further, as she may stop  
21 breathing." On or about February 13, 2015, the Respondent documented an e-mail exchange with  
22 an individual regarding Patient 1's care where he noted that he could not increase Patient 1's  
23 medications because, the "medications are making her respiratory drive to be shut down." The  
24 Respondent also documented that he believed Patient 1 had sleep apnea, that small amounts of  
25 movement cause her to be out of breath, and that he feared stronger pain medications, could "stop  
26 her breathing drive." The Respondent also documented that he mentioned "intense scrutiny"  
27 from the DEA on prescriptions. On or about August 30, 2017, the Respondent documented that  
28 he discussed with Patient 1 that her pain medication levels were already on the high side.



1 the pain management specialist determined Patient 2 was not a good candidate for pain  
2 management, the pain management specialist's office took over Patient 2's chronic pain  
3 management and that office prescribed those medications between 2009 and 2014. The pain  
4 management specialist closed their office in 2014 and Patient 2 returned to Respondent's primary  
5 care practice for continued pain management treatment.

6 25. On or about January 2015, the Respondent prescribed a monthly prescription of 270  
7 10 mg. methadone tablets and a two-month prescription of 60 tablets of 10 mg. diazepam to  
8 Patient 2. The methadone and diazepam prescriptions continued on a monthly basis until June  
9 2016. The MED of these prescriptions was 1080 MED<sup>8</sup> while in combination with a  
10 benzodiazepine. The Respondent suddenly discontinued Patient 2's diazepam prescription in  
11 June 2016. The Respondent continued Patient 2's methadone prescription until October 2016.  
12 On or about November 2016 through September 2019 the Respondent slowly tapered down  
13 Patient 2's methadone prescription. By September 2019, the Respondent was prescribing a  
14 monthly prescription of 120 tablets of 10 mg. methadone tablets to Patient 2. In comparison to  
15 the prescription in January 2015, the prescription in September 2019 had an MED of 320.

16 26. Between December 2013 and May 2019, the Respondent failed to create and/or  
17 document creating a clear treatment plan for Patient 2's chronic pain medication. Between  
18 December 2013 and May 2019, the Respondent failed to perform and/or document performing a  
19 clear and consistent assessment of Patient 2's progress on controlled substances. For example,  
20 during an interview with the Board, the Respondent stated he managed Patient 2's fibromyalgia  
21 but he failed to sufficiently document the care and treatment of fibromyalgia in Patient 2's  
22 medical chart. The Respondent documented multiple diagnoses for Patient 2 between December  
23 2013 and May 2019, including depression, diabetic neuropathy, thoracic neuritis, low back pain,  
24 low back pain syndrome, back pain, chronic low back pain, insomnia, thoracic outlet syndrome,  
25 lumbago, and lumbar stenosis with neurogenic claudication. However, the Respondent failed to  
26 properly detail these diagnoses in Patient 2's medical chart. For example, on or about October

27 <sup>8</sup> The MED was calculated using the following on-line tool.  
28 <http://www.agencymeddirectors.wa.gov/Calculator/DoseCalculator.htm>

1 11, 2016, the Respondent documented that Patient 2 suffered from sciatica but he failed to  
2 properly document a review of systems and/or document a physical examination that supported  
3 his diagnosis of sciatica.

4 27. Between December 2013 and May 2019, the Respondent repeatedly failed to provide  
5 clear clinical objectives in relation to Patient 2's chronic pain management. For example, the  
6 Respondent documented that the goal in March 20, 2019, was to decrease Patient 2's methadone  
7 prescriptions to an amount covered by insurance, not whether that decrease was clinically optimal  
8 for the patient. Between December 2013 and May 2019, the Respondent failed to sufficiently use  
9 pain scales and urine toxicology screens as part of a comprehensive plan to perform periodic  
10 review of Patient 2's progress on chronic pain management. In addition, the Respondent failed to  
11 document why pain scales and urine toxicology screens were not used in Patient 2's chart despite  
12 her high dosing of methadone. Finally, between December 2013 and May 2019, Respondent's  
13 periodic review of Patient 2's progress on chronic pain management relied on Patient 2's  
14 subjective reports of pain rather than on objective clinical findings.

15 28. Between December 2013 and May 2019, the Respondent failed to properly create  
16 and/or document creating a clear and delineated treatment plan for the tapering of Patient 2's  
17 medications. For example, prior to tapering Patient 2's methadone prescription, the Respondent  
18 prescribed the medication to be taken five times per day with no breakthrough pain medicine  
19 option despite methadone having a relatively long half-life for absorption. The Respondent often  
20 listed in the medical chart that Patient 2 should take 1 to 2 tablets of methadone every 6 to 8 hours  
21 "prn<sup>9</sup>". In addition, Respondent continued Patient 2's methadone prescription while tapering  
22 down her prescription based on a subjective review of how much methadone she seemed to need  
23 by examining how much she was using. On or about April 1, 2016, a nurse verbally instructed  
24 Patient 2 to decrease her Valium prescription to 1 tablet daily and referenced instructions from a  
25 March 24, 2016, set of instructions regarding Patient 2 beginning to take Cymbalta. On or about  
26 June 10, 2016, the Respondent provided one last 30-day supply of 60 tablets of 10 mg. Valium.

27  
28 <sup>9</sup> P.R.N., medical abbreviation meaning "when necessary" from the Latin phrase "pro re  
nata."

1 There was no other documentation contained in the medical record regarding the discontinuation  
2 of Valium in Patient 2's chart.

3 29. On or about January 2, 2015, April 26, 2017, and October 22, 2019, Patient 2 entered  
4 into and signed a pain management agreement. The pain management agreement included  
5 information that stated pain medications can cause side effects including making the person  
6 sleepy and slow down reflexes, that alcohol can make pain medication side effects worse, and that  
7 pain medications with narcotics can be addictive. Between December 2013 and May 2019, the  
8 Respondent documented a number of side effects from Patient 2's medication regimen including  
9 constipation, somnolence, falls, balance issues, memory issues, and confusion. However,  
10 Respondent failed to fully counsel and/or document fully counseling Patient 2 that these side  
11 effects may be related to her medications in Patient 2's medical chart.

12 30. Between December 2013 and May 2019, the Respondent failed to properly refer  
13 and/or document referring Patient 2 for specialist services. While there is mention of orthopedics,  
14 neurology, and physical therapy, there is little evidence that the Respondent made sufficient  
15 referrals for Patient 2 to be seen by a pain management specialist and a psychiatric specialist. For  
16 example, on March 20, 2018, there is a letter in Patient 2's chart, which stated she had been  
17 referred to a pain management specialist. On April 11, 2018, there is a message from Patient 2  
18 that the pain management specialist did not manage methadone and that she needed a refill of her  
19 medications, including methadone. The Respondent failed to incorporate any of this information  
20 into his progress notes, and he failed to document whether Patient 2 actually saw the pain  
21 management specialist and whether or not other interventions or efforts at referral to pain  
22 management were made. On February 5, 2019, the Respondent documented that they had been  
23 working "overtime for pain management" but there is no specific information detailed in the  
24 patient's chart regarding progress on the referral. In addition, there is no documentation in the  
25 chart from December 2013 to May 2019 that Patient 2 was referred to psychiatry. On March 22,  
26 2016, the Respondent instructed Patient 2 to abruptly stop taking high dose Zoloft that placed  
27 Patient 2 at increased risk. Despite evidence contained in many of the progress notes between  
28 December 2013 and May 2019, which documented that Patient 2's depression was not well



1 controlled, with high PHQ<sup>10</sup>-9 scores, even including suicidal ideation, the Respondent failed to  
2 refer her for a psychiatric consultation.

3 Patient 3

4 31. The Respondent began seeing Patient 3 in August 2011. Patient 3 had a history of  
5 moderate to severe lumbar disease, stenosis, bad knee arthritis, and advanced knee osteoarthritis.  
6 Patient 3 enjoyed being physically active and pain medication allowed him to continue daily  
7 activities. Patient 3 also had a surgical history that included bi-lateral knee replacement. Patient  
8 3 began receiving Ambien in 2009, testosterone in 2010, and fentanyl in 2007. Patient 3  
9 originally received a 50 mcg patch of fentanyl and that dose was increased in November 2010 to a  
10 75 mcg patch of fentanyl. After taking over Patient 3's care, the Respondent tried a series of  
11 short-acting controlled substances for breakthrough pain including Vicodin, Norco, and  
12 oxycodone. In 2010, Patient 3 had an MRI done which showed radiologic evidence of  
13 degenerative disease in Patient 3's back.

14 32. On or about January 2014, the Respondent prescribed 15 patches of 100 mcg/1 hour  
15 fentanyl and 180 tablets of 20 mg. oxycodone to Patient 3. If taken over 30 days, the MED of  
16 these prescriptions was 420. In addition, the Respondent's prescribing of 15 patches was out of  
17 the normal prescribing pattern for fentanyl patches because the patches are designed to last three  
18 days and a typical prescription for 30 days would be ten patches. According to the Respondent,  
19 Patient 3 complained that on the third day of patch use, the patches were not effective and Patient  
20 3 would replace the patches after two days of use. In reviewing Patient 3 CURES report, the  
21 Respondent prescribed 15 patches of 100 mcg/1 hour fentanyl and 180 tablets of 20 mg.  
22 oxycodone every one to two months to Patient 3 until August 2017. The Respondent then  
23 transitioned Patient 3 from oxycodone to 90 tablets of 10-325 mg hydrocodone with  
24 acetaminophen while keeping him on fentanyl. The Respondent kept Patient 3 on 15 patches of  
25 100 mcg/1 hour fentanyl and 90 tablets of 10-325 mg hydrocodone with acetaminophen through  
26 October 2019. The MED of this fentanyl and hydrocodone with acetaminophen prescription, if  
27 taken over a 30-day period, was 270.

28 <sup>10</sup> PHQ-9 refers to the major depressive disorder (MDD) module of the full PHQ.

1           33. In addition to prescribing fentanyl, oxycodone, and hydrocodone with acetaminophen  
2 to Patient, between December 2013 and May 2019, the Respondent also prescribed 90 tablets of  
3 10 mg. Ambien on six occasions, 20 tablets of 10 mg. diazepam on six occasions, 30 tablets of 10  
4 mg. Ambien on occasion, and 40 tablets of 10 mg. diazepam on two occasions. The Respondent  
5 also continued Patient 3 on testosterone throughout the time-period between December 2013 and  
6 May 2019. In reviewing the CURES report, between August 2016 and December 2016, the  
7 Respondent prescribed a daily dose of one 100 mcg/1 hour fentanyl patches, six tablets of 20 mg.  
8 oxycodone, one tablet of 10 mg. Ambien and two tablets of 10 mg. diazepam on multiple  
9 occasions.

10           34. Between December 2013 and May 2019, the Respondent failed to adequately perform  
11 and/or document performing physical examinations in relation to Patient 3's pain complaints. For  
12 example, the Respondent documented that Patient 3 suffered from neuropathy but failed to  
13 document a physical examination nor work-up document for the condition. On May 23, 2017, the  
14 Respondent documented that Patient 3 had a complaint of foot numbness and the Respondent  
15 ordered an MRI. The Respondent failed to document performing a physical examination of  
16 Patient 3 related to the complaint of foot numbness. On August 7, 2017, the Respondent  
17 documented that Patient 3 had a new problem involving "PAD<sup>11</sup>" with reports of hand and feet  
18 turning white with burning and numbness. Once again the Respondent failed to document  
19 performing a physical examination of Patient 3 other than marking that the extremities had "no  
20 edama." Finally, on March 7, 2018, the Respondent diagnosed Patient 3 with fibromyalgia but  
21 failed to document a relevant physical examination.

22           35. Between December 2013 and May 2019, the Respondent failed to sufficiently use  
23 pain scales and urine toxicology screens as part of a comprehensive plan to perform periodic  
24 review of Patient 3's progress on chronic pain management. In addition, the Respondent failed to  
25 document why pain scales and urine toxicology screens were not used in Patient 3's chart despite  
26 Respondent prescribing high doses of fentanyl and oxycodone. Finally, between December 2013

27 \_\_\_\_\_  
28 <sup>11</sup> PAD may refer to peripheral arterial disease which may also be known as peripheral  
vascular disease (PVD).

1 and May 2019, Respondent's periodic review of Patient 3's progress on chronic pain management  
2 relied on Patient 3's subjective report of pain rather than objective clinical findings.

3 36. On November 24, 2014, May 23, 2017, July 2, 2018, and July 9, 2019, Patient 3  
4 entered into and signed pain management agreements with the Respondent. The pain  
5 management agreements included information that stated pain medications can cause side effects  
6 including making the person sleepy and slow down reflexes, that alcohol can make pain  
7 medication side effects worse, and that pain medications with narcotics can be addictive. The  
8 pain agreements covered fentanyl, oxycodone, Ambien, and hydrocodone with acetaminophen.  
9 They agreements did not mention diazepam. On or about June 6, 2017, Patient 3 requested a  
10 refill of Ambien. The Respondent documented that he advised the patient to not take Ambien  
11 because in combination with pain medications it is dangerous and that the Respondent was  
12 worried about the mixture of medications in Patient 3's system. The Respondent had previously  
13 documented that he discussed the risk of taking with Ambien with Patient 3 on or about March  
14 20, 2017. According to the medical records, most of these concerns were relayed to Patient 3's  
15 wife who stated that Patient 3 only used the medication occasionally. The Respondent refilled  
16 Patient 3's prescription for Ambien on June 8, 2017, December 30, 2017, and March 5, 2018,  
17 despite his stated concerns.

18 37. Between December 2013 and May 2019, the Respondent documented that he referred  
19 Patient 3 for a number of specialist consultations. In 2018, the Respondent referred Patient 3 to a  
20 pain management specialist. On or about September 5, 2018, Patient 3 stated that he saw the pain  
21 management specialist one time but that the injections did not help. The Respondent did not  
22 incorporate the pain management specialist's recommendations and/or evaluations into his  
23 written treatment plan and assessment. The Respondent documented that he would look into a  
24 neuropathy specialist but there was no other documentation related to this referral. The  
25 Respondent failed to refer Patient 3 for a psychiatric referral despite intermittent diagnoses over  
26 the years including depression, anxiety, and insomnia.

27 ///

28 ///

Patient 4

1  
2       38. On or about May 1, 2012, the Respondent began caring for Patient 4 after she  
3 transferred her care from a different provider. Patient 4 had a history of Type-1 diabetes, chronic  
4 back pain with radiation, insomnia and multiple past rib and spine fractures from an accident.  
5 According to the Respondent, Patient 4 was in constant pain and already on chronic opioids,  
6 including fentanyl, Valium, and Restoril when she first saw the Respondent. Patient 4 also  
7 suffered from other medical issues like asthma and high cholesterol. In 2017, Patient 4 was  
8 involved in a serious car accident where she hit an abandoned vehicle on the freeway and it  
9 caused her to have additional pain.

10       39. On or about January 5, 2014, and January 10, 2014, the Respondent prescribed 15  
11 patches of 100 mcg/1 hour fentanyl patches, 120 tablets of 20 mg oxycodone, 180 tablets of 10  
12 mg diazepam and 90 tablets of 30 mg temazepam to Patient 4. The Respondent's prescription of  
13 15 patches was larger than expected as typically a one-month prescription of three-day fentanyl  
14 patches would be for ten total patches. The diazepam and temazepam prescriptions were three  
15 month prescription. Taken as directed, Patient 4 was on an opioid prescription with a daily MED  
16 of 360 in combination with 20 mg of diazepam and 30 mg of temazepam. In reviewing the  
17 CURES printout, the Respondent continued to prescribe oxycodone, diazepam, and temazepam to  
18 Patient 4 until April 2015. Fentanyl was not listed on the CURES profile during that time but  
19 according to both the Respondent and Patient 4, she remained on fentanyl throughout that time.  
20 In April 2015, the Respondent was prescribing 15 patches of 100 mcg/1 hour fentanyl patches,  
21 180 tablets of 20 mg oxycodone, and 90 tablets of 10 mg. diazepam per month to Patient 4. If  
22 taken as prescribed, Patient 4 was on an opioid prescription with a daily MED of 420, in  
23 combination with 30 mg of diazepam and 30 mg of temazepam. The Respondent also continued  
24 Patient 4 on temazepam, having refilled the prescription in March 2015. The Respondent  
25 continued Patient 4's prescriptions on a regular basis until October 2016.

26       40. In February 2017, the CURES showed a final prescription for 90 tablets of 30 mg  
27 temazepam. In September 2017, the CURES showed a final prescription for 60 tablets of 20 mg  
28 oxycodone. In December 2017, the Respondent began prescribing a daily prescription of two

1 tablets of 10-325 mg hydrocodone with acetaminophen to Patient 4, instead of oxycodone, for  
2 breakthrough pain. In October 2018, the Respondent provided one final prescription of 180  
3 tablets of 10/325 mg hydrocodone with acetaminophen to Patient 4. By January 2019, the  
4 Respondent was prescribing only one 10 mg tablet of diazepam per day to Patient 4. The  
5 Respondent continued to prescribe 15 patches of 100 mcg/1 hour per month to Patient 4 through  
6 May 2019.<sup>12</sup>

7 41. Between December 2013 and May 2019, the Respondent documented Patient 4 had  
8 “back pain with radiation.” The Respondent did not perform a physical examination and/or  
9 document performing a physical examination related to Patient 4’s diagnosis of “radiation.” In  
10 addition on or about March 8, 2016, the Respondent documented that Patient 4 complained of  
11 new back and hip pain but failed to perform and/or document performing a review of systems or  
12 physical examination. On December 28, 2017, there was documentation in the medical record  
13 that Patient 4 could not raise one of her arms but Respondent failed to perform and/or document  
14 performing a review of systems or physical examination. Between December 2013 and May  
15 2019, Respondent failed to document why Patient 4 was receiving chronic Valium for back pain.

16 42. On or about March 8, 2016, Patient 4 complained of back spasms and was treated  
17 with baclofen. The Respondent’s documented rationale was that Patient 4 no longer responded to  
18 Valium but the Respondent continued to prescribe Valium after March 8, 2016. On or about  
19 August 10, 2017, the Respondent documented that Patient 4’s benzodiazepine medication could  
20 not be cut back because of Patient 4’s anxiety and “RLS<sup>13</sup>” but those new problems were not  
21 documented before or after the visit on August 10, 2017. In addition, in March 2018, the  
22 Respondent provided Valium as a BID medication and then did not refill it until January 2019.  
23 The Respondent failed to document a plan for weaning Patient 4 off Valium, nor did he provide  
24 an explanation for why there was a nine-month absence in prescribing, nor did he explain why he  
25 was restarting Patient 4’s Valium prescription.

26 \_\_\_\_\_  
27 <sup>12</sup> According to Patient 4’s CURES there were additional gaps in Respondent’s fentanyl  
28 prescribing but both the Respondent and Patient 4 state that she received fentanyl on a consistent  
basis from the Respondent.

<sup>13</sup> RLS commonly refers to Restless Leg Syndrome.

1           43. On or about May 5, 2015, the Respondent documented that he informed Patient 4 that  
2 she had developed a tolerance for benzodiazepines, such as diazepam and temazepam, and he  
3 improperly advised her to stop taking temazepam for one week so the medication would begin  
4 working again. Between December 2013 and May 2019, the Respondent prescribed fentanyl  
5 patches every 48 hours rather than every 72 hours and failed to document what Patient 4 did with  
6 the patches after each use. On or about December 4, 2017, the Respondent documented that  
7 Patient 4 had been in a motor vehicle accident in which she ran into a truck parked sideways on  
8 Highway 49. The Respondent documented that he informed Patient 4 to be "very careful of  
9 taking extra pain meds, you are already in a high dose," and documented that she could take extra  
10 Valium for a short time following the accident. Between December 2013 and May 2019, the  
11 Respondent failed to sufficiently use pain scales and urine toxicology screens as part of a  
12 comprehensive plan to perform periodic review of Patient 4's progress on chronic pain  
13 management. In addition, the Respondent failed to document why pain scales and urine  
14 toxicology screens were not used in Patient 4's chart despite his high dosing of fentanyl and  
15 oxycodone.

16           44. On or about April 20, 2016, August 10, 2017, October 2, 2018, and October 23, 2019,  
17 Patient 4 entered into and signed pain management agreements with the Respondent. The pain  
18 management agreements included information that stated pain medications can cause side effects  
19 including making the person sleepy and slowing down reflexes; that alcohol can make pain  
20 medication side effects worse, and that pain medications with narcotics can be addictive.  
21 Medications covered by the pain management agreements included fentanyl, oxycodone,  
22 temazepam, Valium, and hydrocodone with acetaminophen. The Respondent did document that  
23 he discussed the risks of taking opioids in combination with benzodiazepines with Patient 4. The  
24 Respondent also documented that he discussed the possible use of Narcan with Patient 4.  
25 However, on or about December 4, 2017, the Respondent failed to document whether or not he  
26 discussed with Patient 4 whether she was on her medications at the time of the motor vehicle  
27 accident and whether or not those medications may have contributed to the accident.

28       ///

1 45. Between December 2013 and May 2019, the Respondent failed to refer and/or  
2 document referring Patient 4 for appropriate specialist consultations despite Respondent  
3 prescribing high dose opioids in combination with benzodiazepines. For example, there is no  
4 documentation that the Respondent referred Patient 4 to a pain management specialist to review  
5 her chronic pain care. On or about October 2, 2018, there is documentation in Patient 4's chart  
6 that she would seek a consultation with a "sleep specialist" following a trip, but there is no  
7 follow-up documented in Patient 4's chart on whether that consultation occurred.

8 **FIRST CAUSE FOR DISCIPLINE**

9 **(Gross Negligence)**

10 46. Respondent's license is subject to disciplinary action under section 2234, subdivision  
11 (b), of the Code in that he committed gross negligence during the care and treatment of Patients 1,  
12 2, and 4. The circumstances are as follows:

13 47. Complainant realleges paragraphs 17 through 45, and those paragraphs are  
14 incorporated by reference as if fully set forth herein.

15 48. Respondent's license is subject to disciplinary action because he committed gross  
16 negligence between December 2013 and May 2019, during the care and treatment of Patients 1, 2,  
17 and 4, in the following distinct and separate ways:

18 a. By failing to provide and/or document providing a clear treatment plan and  
19 ongoing assessment for Patient 1 in regards to her chronic pain medications. By failing to  
20 perform and/or document performing periodic review of Patient 1's progress on chronic pain  
21 medications. By failing to provide and/or document providing detailed informed consent to  
22 Patient 1 regarding her chronic pain medications. By failing to arrange and/or document  
23 arranging for appropriate specialist consultations for Patient 1 regarding her chronic pain  
24 medications and general medical care;

25 b. By failing to perform and/or document performing physical examinations  
26 related to Patient 2's pain conditions. By failing to provide and/or document providing a clear  
27 treatment plan and ongoing assessment for Patient 2 in regards to her chronic pain medications.  
28 By failing to perform and/or document performing periodic review of Patient 2's progress on

1 chronic pain medications. By failing to provide and/or document providing detailed informed  
2 consent to Patient 2 regarding her chronic pain medications. By failing to arrange and/or  
3 document arranging for appropriate specialist consultations for Patient 2 regarding her chronic  
4 pain medications and general medical care; and,

5 c. By failing to perform and/or document performing physical examinations  
6 related to Patient 4's pain conditions. By failing to provide and/or document providing a clear  
7 treatment plan and ongoing assessment for Patient 4 in regards to her chronic pain medications.  
8 By failing to perform and/or document performing periodic review of Patient 4's progress on  
9 chronic pain medications. By failing to provide and/or document providing detailed informed  
10 consent to Patient 4 regarding her chronic pain medications. By failing to arrange and/or  
11 document arranging for appropriate specialist consultations for Patient 4 regarding her chronic  
12 pain medications and general medical care.

### 13 **SECOND CAUSE FOR DISCIPLINE**

#### 14 **(Repeated Negligent Acts)**

15 49. Respondent's license is subject to disciplinary action under 2234, subdivision (c), in  
16 that he committed repeated negligent acts during the care and treatment of Patients 1, 2, 3 and 4.  
17 The circumstances are as follows:

18 50. Complainant realleges paragraphs 17 through 48, and those paragraphs are  
19 incorporated by reference as if fully set forth herein.

20 51. The gross departures from the standard of care as set forth in paragraph 45, are  
21 incorporated by reference as if fully set forth herein and serve as repeated negligent acts.

22 52. In addition to the repeated negligent acts involving Patients 1, 2, and 4, the  
23 Respondent also engaged in repeated negligent acts with Patient 3 including the following:

24 a. By failing to perform and/or document performing physical examinations  
25 related to Patient 3's pain conditions;

26 b. By failing to provide and/or document providing a clear treatment plan and  
27 ongoing assessment for Patient 3 in regards to his chronic pain medications;

28



1 c. By failing to perform and/or document performing periodic review of Patient  
2 3's progress on chronic pain medication;

3 d. By failing to provide and/or document providing detailed informed consent  
4 to Patient 3 regarding his chronic pain medications; and

5 e. By failing to arrange and/or document arranging for appropriate specialist  
6 consultations for Patient 3 regarding his chronic pain medications and general medical care.

7 **THIRD CAUSE FOR DISCIPLINE**

8 **(Inadequate and Inaccurate Medical Records)**

9 53. Respondent's license is subject to disciplinary action under section 2266 in that he  
10 failed to properly keep adequate and accurate medical records for Patients 1, 2, 3, and 4. The  
11 circumstances are as follows:

12 54. Complainant realleges paragraphs 17 through 52 and those paragraphs are  
13 incorporated by reference as if fully set forth herein.

14 ///  
15 ///  
16 ///  
17 ///  
18 ///  
19 ///  
20 ///  
21 ///  
22 ///  
23 ///  
24 ///  
25 ///  
26 ///  
27 ///  
28 ///

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

PRAYER

WHEREFORE, Complainant requests that a hearing be held on the matters herein alleged, and that following the hearing, the Medical Board of California issue a decision:

1. Revoking or suspending Physician's and Surgeon's Certificate Number C 51972, issued to Ali Mokhlesi, M.D.;


2. Revoking, suspending or denying approval of Ali Mokhlesi, M.D.'s authority to supervise physician assistants and advanced practice nurses;

3. Ordering Ali Mokhlesi, M.D., to pay the Medical Board of California the reasonable costs of the investigation and enforcement of this case pursuant to Bus. & Prof. Code 125.3<sup>14</sup>, and, if placed on probation, to pay the Board the costs of probation monitoring; and

4. Ordering Ali Mokhlesi, M.D., if placed on probation, to notify his patients of his probation status pursuant to Business and Professions Code § 2228.1

5. Taking such other and further action as deemed necessary and proper.

DATED: MAR 01 2022

  
WILLIAM PRASIFKA  
Executive Director  
Medical Board of California  
Department of Consumer Affairs  
State of California  
*Complainant*

SA2020303664  
35847656.docx

<sup>14</sup> Costs of the investigation and enforcement of this case after January 1, 2022.